TrialMolecular cancer research : MCR2021

High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab.

Chung-Han Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.